CDC identities a potential safety signal with Bivalent vaccines

January 14 | Posted by mrossol | Democrat Party, Health, Vaccine

By Vinay Prasad, Jan 13, 2023

Source: CDC identities a potential safety signal with Bivalent vaccines

This administration’s vaccine policy has been horrible, and always erred on the side of pushing doses. They initially denied the safety signal of myocarditis. They delayed pulling J&J in young women. They never banned Moderna in young men. And they rubber-stamped kids vaccines with inadequate efficacy data. All the while, they made no exemption for prior infection. They pushed vaccines in a reckless way, so much so that Marion Gruber and Phil Krause resigned from FDA’s vaccine division. The worst offenders have been: Walensky, Murthy, Jha, Califf, Fauci and Marks.

Most recently, long after the emergency phase of the pandemic ended, this administration granted EUA to the bivalent booster (down to 5 year olds!) based initially on mouse data, and, to this day, supported only by confounded observational studies. Arguably this is an illegal action as there is no emergency to justify boosting 20 year old men who had 3 doses.

Sensible doctors knew this was an error, as did the American people. Less than 20% signed up for the booster.

Pfizer had a 100 billion reason they should have performed and RCT, but this administration felt it better they save that money than run a study.

Now a reminder comes why this was bad policy. On Friday the 13th

We know very little, but it appears a safety signal of stroke may be identified. Of course, there is nothing magic about 65, so it may also occur at younger ages. What is the absolute risk? Where is the press conference? Sadly, no further info followed.

A sensible FDA commish would hold a press conference and state what was known. Instead of that, our FDA commish tweets a picture of himself in a grow house.

Who told him that the best way to handle the announcement of a novel vaccine safety signal was to immerse yourself in lettuce?

Bottom line is: when you approve products without RCTs that can prove a net clinical benefit, even modest safety signals can be devastating.

This administration is playing fast and loose with the agencies credibility. If this safety signal turns out to be salient. Their reputation will rightly be in tatter.

They may not care, but reputation matters.